Wegovy

Novo Nordisk shares slide despite earnings beat on Wegovy pill miss

Novo Nordisk shares fell more than 6% on Tuesday after the Danish drugmaker released its second-quarter 2026 earnings a day ahead of schedule, with investors seizing on a narrow miss in oral Wegovy sales and a cautious full-year outlook despite…

EU approves Wegovy pill as first oral weight-loss drug

Novo Nordisk announced Wednesday that the European Commission has approved its once-daily oral Wegovy pill for weight management in adults with obesity, making it the first GLP-1 receptor agonist available in tablet form across all 27 EU member states.

Wegovy is only obesity drug linked to reduced death risk, BMJ analysis finds

A comprehensive analysis published in The BMJ on July 8 found that subcutaneous semaglutide — marketed as Wegovy — is the only obesity drug associated with reduced risks of death, heart attack, and heart failure, reinforcing Novo Nordisk's position in…

Novo Nordisk shares climb as oral Wegovy success offsets ransomware crisis

Novo Nordisk shares climbed more than 5% on Friday as investors looked past a ransomware incident and focused on the runaway success of the company's oral Wegovy pill and approaching Medicare coverage for GLP-1 weight-loss drugs.